To prevent ticking off a box and to ensure that patient involvement is systemic and sustainable, we have to move into patient-centricity 2.0. What does this mean and how is this done so we can turn the patient voice into value, impact, and benefit?

This session presented at the 2nd annual Patients as Partners EU meeting, which took place January 2018 in London, demonstrates best practices from Hoffman La Roche, Melanoma Patient Network, Patient Focused Medicines Development, and European Patients Forum.

Moderated by: Bettina Ryll, PhD, Founder, Melanoma Patient Network Europe.

Panelists:

Nicola Bedlington, Secretary General, European Patients Forum
Nicholas Brooke, Chief Executive Officer, Patient Focused Medicines Development (PFMD)
Irmi Gallmeier, Senior International Health Policy Leader, Patient Relations, F. Hoffman La Roche

The 3rd annual Patients as Partners EU meeting will take place January 28-29, 2019 in London, UK. Find more information here.

How to Make Patient Involvement Sustainable Throughout Medicines Development

Share

Embed